ASCO 2016 Ovarian Cancer ( 3 articles 1 author) Cancer Network Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, June 10, 2016

ASCO 2016 Ovarian Cancer ( 3 articles 1 author) Cancer Network



Cancer Network
 ASCO 2016 Ovarian Cancer, Gynecologic Cancers, Ovarian Cancer


Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

0 comments :

Post a Comment

Your comments?